GLABF.US Gemina Laboratories Ltd

Healthcare Biotechnology USA Stocks
0.0500 USD
Close of Nov 14, 2026
0.0375 0.3439
Market cap
USD 3.83M
P/E
-
P/B
44.10x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jan 2026.

Is GLABF.US undervalued?

Graham number

The Graham number of Gemina Laboratories Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Gemina Laboratories Ltd fundamental analysis

No fundamental analysis for Gemina Laboratories Ltd yet.

Gemina Laboratories Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Gemina Laboratories Ltd

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.

Full company profile